These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 10029712)
1. [Update on mechanisms of drug resistance]. Chauffert B; Correia M; Sergent C Bull Cancer; 1999 Jan; 86(1):97-103. PubMed ID: 10029712 [No Abstract] [Full Text] [Related]
2. Recent advances in P-glycoprotein-mediated multidrug resistance reversal mechanisms. Li X; Li JP; Yuan HY; Gao X; Qu XJ; Xu WF; Tang W Methods Find Exp Clin Pharmacol; 2007 Nov; 29(9):607-17. PubMed ID: 18193112 [TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges. Zhang D; Fan D Expert Rev Anticancer Ther; 2007 Oct; 7(10):1369-78. PubMed ID: 17944563 [TBL] [Abstract][Full Text] [Related]
4. A review of selected anti-tumour therapeutic agents and reasons for multidrug resistance occurrence. Sawicka M; Kalinowska M; Skierski J; Lewandowski W J Pharm Pharmacol; 2004 Sep; 56(9):1067-81. PubMed ID: 15324475 [TBL] [Abstract][Full Text] [Related]
5. [Platinum salts: cytotoxic mechanisms of action, mechanisms of resistance of cancer cells, interactions with ionizing radiation, specificity of carboplatin]. Rixe O Bull Cancer; 2000 Aug; 87 Spec No():7-15. PubMed ID: 11082717 [TBL] [Abstract][Full Text] [Related]
6. (+/-)-3'-O, 4'-O-dicynnamoyl-cis-khellactone, a derivative of (+/-)-praeruptorin A, reverses P-glycoprotein mediated multidrug resistance in cancer cells. Shen X; Chen G; Zhu G; Fong WF Bioorg Med Chem; 2006 Nov; 14(21):7138-45. PubMed ID: 16875827 [TBL] [Abstract][Full Text] [Related]
7. Mechanisms and functional aspects of multidrug resistance in Ehrlich ascites tumour cells. Nielsen DL Dan Med Bull; 2004 Nov; 51(4):393-414. PubMed ID: 16009064 [No Abstract] [Full Text] [Related]
8. Heat shock-independent induction of multidrug resistance by heat shock factor 1. Tchénio T; Havard M; Martinez LA; Dautry F Mol Cell Biol; 2006 Jan; 26(2):580-91. PubMed ID: 16382149 [TBL] [Abstract][Full Text] [Related]
10. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure. Matsumoto Y; Takano H; Nagao S; Fojo T Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765 [TBL] [Abstract][Full Text] [Related]
11. Cisplatin. Reed E Cancer Chemother Biol Response Modif; 1999; 18():144-51. PubMed ID: 10800481 [No Abstract] [Full Text] [Related]
12. [JM216, an orally active platine derivative]. Lansiaux A; Bailly C Bull Cancer; 2000 Jul; 87(7-8):531-6. PubMed ID: 10969209 [No Abstract] [Full Text] [Related]
13. Influence of IL-6 on MDR and MRP-mediated multidrug resistance in human hepatoma cells. Lee G; Piquette-Miller M Can J Physiol Pharmacol; 2001 Oct; 79(10):876-84. PubMed ID: 11697747 [TBL] [Abstract][Full Text] [Related]
14. The great multidrug-resistance paradox. Chen VY; Rosania GR ACS Chem Biol; 2006 Jun; 1(5):271-3. PubMed ID: 17163753 [TBL] [Abstract][Full Text] [Related]
16. The role of DNA adduct structure and conformation in cisplatin resistance. Lloyd D Trends Pharmacol Sci; 2002 Apr; 23(4):158. PubMed ID: 11931981 [No Abstract] [Full Text] [Related]
17. P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential. Alemán C; Annereau JP; Liang XJ; Cardarelli CO; Taylor B; Yin JJ; Aszalos A; Gottesman MM Cancer Res; 2003 Jun; 63(12):3084-91. PubMed ID: 12810633 [TBL] [Abstract][Full Text] [Related]
18. Reversal of cancer multidrug resistance by green tea polyphenols. Mei Y; Qian F; Wei D; Liu J J Pharm Pharmacol; 2004 Oct; 56(10):1307-14. PubMed ID: 15482646 [TBL] [Abstract][Full Text] [Related]